Title |
Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan
|
---|---|
Published in |
BMC Pulmonary Medicine, June 2016
|
DOI | 10.1186/s12890-016-0253-x |
Pubmed ID | |
Authors |
Keishi Oda, Kazuhiro Yatera, Yoshihisa Fujino, Hiroshi Ishimoto, Hiroyuki Nakao, Tetsuya Hanaka, Takaaki Ogoshi, Takashi Kido, Kiyohide Fushimi, Shinya Matsuda, Hiroshi Mukae |
Abstract |
Some IPF patients show a rapid progression of respiratory failure. Most patients are treated with high-dose corticosteroids. However, no large clinical studies have investigated the prognosis or efficacy of combined treatments including high-dose corticosteroids in IPF patients with a rapid progression of respiratory failure. We enrolled IPF patients who received mechanical ventilation and high-dose corticosteroids between April 2010 and March 2013. Records were extracted from a Japanese nationwide inpatient database. We conducted a retrospective epidemiologic and prognostic analysis. Two hundred nine patients receiving an average of 12.8 days of ventilatory support were enrolled. There were 138 (66 %) fatal cases; the median survival was 21 days. The short-term (within 30 days) and long-term (within 90 days) survival rates were 44.6 and 24.6 %, respectively. The average monthly admission rate among the IPF patients with the rapid progression of respiratory failure in the winter was significantly higher than that in spring (p = 0.018). Survival did not differ to a statistically significant extent in the different geographic areas of Japan. Survivors were significantly younger (p = 0.002) with higher rates of mild dyspnea on admission (p = 0.012), they more frequently underwent bronchoscopy (p < 0.001), and received anticoagulants (p = 0.027), co-trimoxazole (p < 0.001) and macrolide (p = 0.02) more frequently than non-survivors. A multivariate logistic analysis demonstrated that two factors were significantly associated with a poor prognosis: >80 years of age (OR = 2.94, 95 % Cl 1.044-8.303; p = 0.041) and the intravenous administration of high-dose cyclophosphamide (OR = 3.17, 95 % Cl 1.101-9.148; p = 0.033). Undergoing bronchoscopy during intubation (OR = 0.25, 95 % Cl 0.079-0.798; p = 0.019) and the administration of co-trimoxazole (OR = 0.28, 95 % Cl 0.132-0.607; p = 0.001) and macrolides (OR = 0.37, 95 % Cl 0.155-0.867; p = 0.033) were significantly associated with a good prognosis. The dosage of co-trimoxazole significantly correlated with survival. Co-trimoxazole and macrolides may be a good addition to high-dose corticosteroids in the treatment of IPF patients with a rapid progression of respiratory failure. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 57 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 14% |
Other | 6 | 11% |
Student > Master | 5 | 9% |
Student > Doctoral Student | 4 | 7% |
Student > Postgraduate | 4 | 7% |
Other | 14 | 25% |
Unknown | 16 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 53% |
Immunology and Microbiology | 4 | 7% |
Engineering | 2 | 4% |
Social Sciences | 1 | 2% |
Chemistry | 1 | 2% |
Other | 1 | 2% |
Unknown | 18 | 32% |